Nothing Special   »   [go: up one dir, main page]

DK1163008T3 - Use of trehalose to stabilize a liquid vaccine - Google Patents

Use of trehalose to stabilize a liquid vaccine

Info

Publication number
DK1163008T3
DK1163008T3 DK00912734T DK00912734T DK1163008T3 DK 1163008 T3 DK1163008 T3 DK 1163008T3 DK 00912734 T DK00912734 T DK 00912734T DK 00912734 T DK00912734 T DK 00912734T DK 1163008 T3 DK1163008 T3 DK 1163008T3
Authority
DK
Denmark
Prior art keywords
trehalose
liquid vaccine
stabilize
vaccine composition
liquid
Prior art date
Application number
DK00912734T
Other languages
Danish (da)
Inventor
Graf Sandrine Lentsch
Jean-Rene Cartier
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of DK1163008T3 publication Critical patent/DK1163008T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention concerns a liquid vaccine composition comprising at least an antigen consisting of a polysaccharide bound to a carrier protein and trehalose. The invention also concerns a method for stabilising a liquid vaccine composition which consists in adding trehalose to the vaccine composition.
DK00912734T 1999-03-23 2000-03-23 Use of trehalose to stabilize a liquid vaccine DK1163008T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903765A FR2791895B1 (en) 1999-03-23 1999-03-23 USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
PCT/FR2000/000730 WO2000056365A1 (en) 1999-03-23 2000-03-23 Use of trehalose for stabilising a liquid vaccine

Publications (1)

Publication Number Publication Date
DK1163008T3 true DK1163008T3 (en) 2003-11-17

Family

ID=9543654

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912734T DK1163008T3 (en) 1999-03-23 2000-03-23 Use of trehalose to stabilize a liquid vaccine

Country Status (11)

Country Link
EP (1) EP1163008B1 (en)
JP (1) JP2002540079A (en)
AT (1) ATE246937T1 (en)
AU (1) AU3438900A (en)
CA (1) CA2366869A1 (en)
DE (1) DE60004496T2 (en)
DK (1) DK1163008T3 (en)
ES (1) ES2200845T3 (en)
FR (1) FR2791895B1 (en)
PT (1) PT1163008E (en)
WO (1) WO2000056365A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283012T3 (en) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. HELICOBACTER PYLORI BACTERIOFERRITINE.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
US10272147B2 (en) 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups
US8765135B2 (en) 2003-10-02 2014-07-01 Novartis Ag Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
WO2007132480A2 (en) * 2006-05-12 2007-11-22 Bharat Biotech International Limited A composition useful as a vaccine
CN103357003A (en) 2006-09-07 2013-10-23 葛兰素史密丝克莱恩生物有限公司 Vaccine
EP2142211A1 (en) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Vaccine
KR20160005378A (en) 2007-09-14 2016-01-14 사노피 파스테르 바이오로직스, 엘엘씨 Pharmaceutical compositions containing clostridium difficile toxoids a and b
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
CN102596254B (en) 2009-09-30 2016-10-19 诺华股份有限公司 Coupling of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
WO2011110636A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201016969D0 (en) 2010-10-08 2010-11-24 Genome Res Ltd Expression system
EP2524701A3 (en) 2011-05-20 2012-12-19 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
CN103917245B (en) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 Method for preparing glycoprotein glycoconjugate
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
CA2874210A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
FR2992656B1 (en) * 2012-07-02 2016-10-07 Sanofi Pasteur METHOD FOR PRODUCING ANTIGENS HAEMOPHILUS INFLUENZAE TYPE B
CN104487086B (en) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 Non-animal derived nonalcoholic vaccine composition and preparation method thereof
EP3482770B1 (en) 2012-10-03 2020-11-25 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
PT2939025T (en) * 2012-12-28 2018-07-31 Cellestis Ltd A cell mediated immune response assay
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
PL3506935T3 (en) 2016-09-02 2024-06-10 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
WO2018048869A1 (en) 2016-09-06 2018-03-15 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
US20180264095A1 (en) 2017-03-03 2018-09-20 Treos Bio Zrt Population-based immunogenic peptide identification platform
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
KR20210086612A (en) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 peptide vaccine
AR117191A1 (en) 2018-11-06 2021-07-21 Glaxosmithkline Biologicals Sa IMMUNOGENIC COMPOSITIONS
GB201908332D0 (en) 2019-06-11 2019-07-24 Univ Oxford Innovation Ltd Assays and inhibitors of oxygen-dependent N-terminal oxidation
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
JP2023520562A (en) 2020-04-03 2023-05-17 ペップティーシー ヴァクシーンズ リミテッド coronavirus vaccine
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
GB202109082D0 (en) 2021-06-24 2021-08-11 Univ Oxford Innovation Ltd Polypeptides and uses thereof
EP4472659A1 (en) 2022-02-03 2024-12-11 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en) 2022-06-14 2022-07-27 Univ Oxford Innovation Ltd Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748132A1 (en) * 1977-10-27 1979-05-03 Behringwerke Ag STABILIZER FOR POLYSACCHARIDE
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
ATE183241T1 (en) * 1993-05-17 1999-08-15 Akzo Nobel Nv VACCINE AGAINST STREPTOCOCCUS SUIS INFECTION
JP4142095B2 (en) * 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド Method for preventing aggregation of various substances during rehydration or melting, and composition obtained by the method
EP0939648B1 (en) * 1996-09-26 2007-11-07 Merck & Co., Inc. Rotavirus vaccine formulations
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines

Also Published As

Publication number Publication date
ES2200845T3 (en) 2004-03-16
FR2791895A1 (en) 2000-10-13
DE60004496T2 (en) 2004-04-08
PT1163008E (en) 2003-12-31
FR2791895B1 (en) 2001-06-15
CA2366869A1 (en) 2000-09-28
AU3438900A (en) 2000-10-09
ATE246937T1 (en) 2003-08-15
EP1163008B1 (en) 2003-08-13
DE60004496D1 (en) 2003-09-18
JP2002540079A (en) 2002-11-26
WO2000056365A1 (en) 2000-09-28
EP1163008A1 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
DK1163008T3 (en) Use of trehalose to stabilize a liquid vaccine
CY2019029I2 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
UA93855C2 (en) Neutralizing epitope-based growth enhancing vaccine
DK1098649T3 (en) Method for Stabilizing Pharmaceutical Compositions with Special Use of Antioxidant
ATE289640T1 (en) AMIDOFUNCTIONAL AMINOPOLYDIORGANOSILOXANES
DE60144145D1 (en) Subtilisin variant
DK1914244T3 (en) Method for modulating the activity of functional immune molecules.
DE69431358D1 (en) METHOD AND COMPOSITIONS FOR MICRO-ENCLOSURE ADJUVANTS
DE60007095D1 (en) CALANOLIDE FOR INHIBITING BTK
FI20012281A0 (en) Method and system for generating personalized messages
ATE551069T1 (en) MUCIN FUSION POLYPEPTIDE VACCINES, COMPOSITIONS AND USE THEREOF
NO20031860D0 (en) Kahalaolid F
ATE297761T1 (en) PREPARATIONS FOR STABILIZING PEG-INTERFERON ALPHA CONJUGATES
DK1147212T3 (en) T-helper cell epitopes
DE69840637D1 (en) COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINES USING CHEMOKINS
DK1235579T3 (en) Pharmaceuticals containing trimegestone
MXPA03002875A (en) VACCINE COMPOSITION AND STABILIZATION METHOD.
ATE352315T1 (en) NEOSPORA VACCINE
DE60222296D1 (en) VACCINATED VIRUS AND METHOD FOR THE PRODUCTION THEREOF
DE10292736D2 (en) Flooring
ATE255594T1 (en) HEPATITIS B INHIBITORS
DE69830156D1 (en) COMPOSITIONS FOR IMMUNE IMPROVEMENT OF VACCINES
IT1308583B1 (en) CONSOLIDATION PROCEDURE FOR LAND AND BUILDINGS.
BR0110205A (en) Peptide deformylase inhibitors
ATE375170T1 (en) ADJUVANT COMBINATIONS FOR IMMUNIZATION AND VACCINES